Dr. Fauci praises Dr. Lisa Baumann Kreuziger for her work on national COVID-19 panel
Dr. Lisa Baumann Kreuziger, MD, MS, Medical Director at the Versiti Blood Center of Wisconsin, was praised in a personal letter of gratitude from White House advisor and director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci.
A hematology expert, Dr. Baumann Kreuziger is serving on a national COVID-19 panel that recommends the best treatment options for people with the virus. The guidelines have been developed to inform clinicians how to care for patients with COVID-19, she says.
"You responded in an exceptional way and worked tirelessly to develop an outstanding initial set of guidelines in two weeks," wrote Dr. Fauci. "In the first week after their release on April 21, there were more than 1 million page views, highlighting the importance of your work. Thank you again for your contributions to this panel, for your outstanding work in caring for patients and for all the additional ways you are helping to respond to this pandemic during this most extraordinary time."
Says Dr. Baumann Kreuziger, "I was honored and humbled to be part of a group of experts to establish treatment recommendations. The guidelines have provided a review of evidence on which doctors can treat patients and develop research."
Abstracts at ASH 2020
For an updated listing of HTRS members' accepted abstracts at ASH 2020 -- oral and poster presentations, as well as special interest sessions, CLICK HERE
NHLBI News: Blueprint, Strategies and Tools for Future Factor VIII Inhibitor-Related Research
Factor VIII Inhibitor State of the Science Workshop Proceedings were published in the July 2019 edition of Hemophilia - Volume 24, Issue 4.
Abstracts from 2019 Symposium published in Haemophilia
The Abstracts from the HTRS/NASTH 2019 Scientific Symposium were published in Haemophilia, the official journal of HTRS.
Podcast: NHLBI Resources and Grants for Hematologists
How to maximize research training and funding opportunities for non-malignant hematology and blood science investigators is the subject of this free podcast, in which Dr. Donna DiMichele and Dr. Keith Hoots of the National Heart, Lung, and Blood Institute (NHLBI) talk about NHLBI and National Institutes of Health resources and grants available to hematologists.
Join a Registry
The Children’s Hospital-Acquired Thrombosis (CHAT) Study
Rare Bleeding Disorders Elevated on the National Health Agenda
New Commitment from National Hemophilia Program Coordinating Center and Treatment Centers
Hemophilia has been named recently as one of only two rare bleeding disorders in Healthy People 2030 (HP2030), identified as a pressing public health issue alongside conditions such as cancer, diabetes, and heart disease. Released by the U.S. Department of Health and Human Services in August 2020, HP2030 is a focused list of national objectives that aims to track and improve the health and well-being of society over the next decade.
One of these priorities, BDBS-01, will strive to reduce the proportion of people with severe hemophilia who have more than four joint bleeds per year. Inclusion of BDBS-01 is significant for the hemophilia community.
"Inclusion of bleeding disorders as a priority on the national health agenda is an important achievement and has resulted from a coordinated, dedicated advocacy by our community," said HTRS Member Amy Shapiro, MD, CEO and co-medical director at the Indiana Hemophilia & Thrombosis Center, Inc., a member HTC within the Great Lakes Regional Hemophilia Network. "Together with our federal partners and treatment centers across the country, we are committed to achieving this goal."
Data on BDBS-01 is gathered at more than 140 HTCs in the U.S. through the Community Counts: CDC Public Health Surveillance Project for Bleeding Disorders on individuals of all severity of disease. HTC diligence has assisted in elevating these chronic conditions to a level of national public health awareness.
To learn more, click:
Newly published in Blood Advances:
2020 ASH Clinical Practice Guidelines on Treatment of Deep Vein Thrombosis and Pulmonary Embolism
The 2020 ASH Clinical Practice Guidelines on Treatment of Deep Vein Thrombosis and Pulmonary Embolism have been published in Blood Advances.
To access, CLICK HERE
You may also copy and paste the following URL in your browser:
2020 ASH ISTH NHF WFH Clinical Practice Guidelines on von Willebrand Disease
The ASH ISTH NHF WFH Clinical Practice Guidelines on von Willebrand Disease have been published in Blood Advances.
To access, CLICK HERE or download these documents:
HTRS members are also encouraged to review a new proposal for definitions in von Willebrand Disease that was recently published in Blood Advances.
To access this proposal, CLICK HERE.
NHF: Research Project Funding Opportunities
The National Hemophilia Foundation (NHF) offers funding opportunities for bleeding disorders investigators at all career stages who are interested in inherited bleeding disorders research or clinical projects.
Application deadlines are approaching in February, March, April and May 2021. For a full listing of award opportunities, please CLICK HERE.
The Jeanne Marie Lusher Predoctoral Diversity Fellowship seeks research applicants from communities of color and/or those that are nationally underrepresented with the aim of increasing diversity in benign hematology. For more info, CLICK HERE.
Questions, Contact NHF's Research Department at [email protected].
National Institutes of Health Center for Scientific Review
The Center for Scientific Review (CSR) at the National Institutes of Health (NIH) offers two programs that could be valuable for HTRS members:
EARLY CAREER REVIEWER PROGRAM:
Early career scientists who would like review experience can apply to participate in the NIH Early Career Reviewer (ECR) Program. The goals of the ECR Program are to help early career scientists become more competitive as grant applicants through first-hand experience with peer review and to enrich and diversify CSR's pool of trained reviewers.
For more info or to apply to the ECR Program, please CLICK HERE
SCIENTIFIC SOCIETY- REVIEWER RECOMMENDATIONS PORTAL:
HTRS members are invited to recommend scientists to serve as grant reviewers through the NIH Review Recommendation portal. Reviewers should be scientists who are generally willing to serve as reviewers and are seen as experts, with integrity, in their field. They should have an active research program, extramural funding, and not currently be a standing member of an NIH study section or advisory council. The NIH is encouraging HTRS to recommend productive scientists from diverse backgrounds and career stages – e.g. assistant, associate, and full professors.
If you would like HTRS to nominate you or a colleague as an NIH reviewer, please email [email protected] for more info.